Envista Holdings Corporation NVST R3KPHARMA
Company Overview
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $2.72B (+8.3% YoY); net profit $47.00M.
- Trailing 12 Months Year-on-year growth — revenue +7.1%, earnings +111.3%.
- 5-Year Trend Long-term compounding — revenue CAGR -0.5%, profit CAGR -23.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -0.47% |
| 1 Year: | 7.10% |
Compounded Profit Growth
| 5 Years: | -23.30% |
| 1 Year: | 111.30% |
Stock Price Performance
| 1 Year: | +24.35% |
| 6 Months: | +0.41% |
| 3 Months: | +14.38% |
| 1 Month: | -4.76% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)44.82 · Neutral
P/E of 46.22 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -0.5% CAGR over 5 years.
- Earnings shrank at -23.3% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NVST Envista Holdings Corporation R3KPHARMA | 26.81 | 46.22 | $4.31B | 0.00% | 4.89% | 3.06% | -0.47% | -23.30% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Apr 2020 | Jul 2020 | Oct 2020 | Dec 2020 | Apr 2021 | Jul 2021 | Oct 2021 | Dec 2021 | Apr 2022 | Jul 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 672.60M | 733.40M | 679.50M | 759.00M | 659.70M | 712.10M | 659.30M | 720.50M | 456.20M | 309.40M | 547.20M | 616.30M | 612.60M | 637.20M | 607.30M | 651.80M | 631.40M | 645.80M | 631.10M | 627.20M | 662.40M | 631.30M | 623.60M | 633.10M | 601.00M | - | 616.90M | 682.10M | 669.90M | 750.60M | 705.50M | 705.50M | 730.50M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 280.90M | 312.20M | 299.70M | 340.00M | 315.40M | - | - |
| Gross Profit | 375.50M | 423.20M | 380.90M | 422.20M | 363.10M | 393.60M | 367.00M | 389.40M | 251.40M | 155.00M | 308.40M | 340.00M | 358.40M | 368.60M | 356.30M | 343.20M | 374.10M | 369.80M | 364.70M | 362.70M | 378.60M | 363.30M | 356.30M | 326.60M | 317.30M | - | 336.00M | 369.90M | 370.20M | 410.60M | 390.10M | 390.10M | 407.00M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 288.60M | 323.60M | 312.70M | 317.60M | 323.90M | - | - |
| Operating Income | - | - | 81.40M | - | 44.90M | 75.90M | 78.70M | - | -25.00M | -107.90M | 61.60M | - | 95.10M | 83.30M | 81.70M | - | 91.50M | 65.20M | 74.50M | 72.10M | 78.90M | 83.30M | 48.10M | -1.15B | 20.90M | - | 47.40M | 46.30M | 57.50M | 93.00M | 66.20M | 62.50M | 80.30M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.60M | 87.30M | 96.70M | 105.90M | 97.90M | - | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.30M | 8.00M | 9.00M | 10.30M | 7.40M | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.00M | 40.70M | 49.90M | 57.60M | 52.20M | - | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.00M | 14.30M | 80.20M | 24.70M | 13.50M | - | - |
| Net Income | 36.60M | 78.80M | 64.10M | 51.20M | 37.90M | 61.50M | 62.10M | 56.10M | -17.20M | -93.50M | 35.60M | 108.40M | 71.70M | 90.10M | 92.90M | - | 74.90M | 47.10M | 47.60M | 43.80M | 51.90M | 21.50M | 23.60M | -1.15B | 8.20M | - | 18.00M | 26.40M | -30.30M | 32.90M | 38.70M | 38.70M | 53.70M |
| Diluted EPS | 0.29 | 0.62 | 0.50 | 0.40 | 0.30 | 0.48 | 0.48 | 0.35 | -0.08 | -0.37 | 0.14 | 0.54 | 0.41 | 0.51 | 0.52 | 0.24 | 0.42 | 0.26 | 0.27 | 0.25 | 0.29 | 0.12 | 0.14 | -6.69 | 0.05 | - | 0.10 | 0.16 | -0.18 | 0.20 | 0.23 | 0.23 | 0.33 |
| R&D Expense | - | - | 42.30M | - | 43.30M | 39.70M | 36.30M | - | 34.70M | 16.50M | 20.00M | - | 25.80M | 25.90M | 24.00M | - | 24.40M | 25.10M | 26.00M | 24.50M | 26.80M | 22.30M | 23.30M | 23.60M | 25.50M | - | 25.30M | 28.30M | 28.30M | - | - | 30.00M | 30.40M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.81B | 2.84B | 2.28B | 1.93B | - | 2.57B | 2.57B | 2.51B | 2.72B |
| Cost of Revenue | - | - | - | - | - | 1.09B | 1.13B | 1.14B | 1.23B |
| Gross Profit | 1.62B | 1.60B | 1.35B | 1.05B | - | 1.47B | 1.44B | 1.37B | 1.49B |
| Operating Expenses | - | - | - | - | - | 1.13B | 1.13B | 1.24B | 1.25B |
| Operating Income | 386.60M | 298.40M | 235.70M | 43.50M | - | 343.20M | 314.90M | 137.20M | 235.80M |
| EBITDA | - | - | - | - | - | 484.40M | 171.10M | -883.80M | 364.50M |
| Interest Expense | - | - | - | - | - | 38.40M | 63.40M | 46.40M | 36.60M |
| Pretax Income | - | - | - | - | - | 283.90M | -54.90M | -1.08B | 177.20M |
| Tax Provision | - | - | - | - | - | 45.90M | 45.30M | 33.90M | 130.20M |
| Net Income | 301.10M | 230.70M | 217.60M | 33.30M | - | 243.10M | -100.20M | -1.12B | 47.00M |
| Diluted EPS | 2.35 | 1.80 | 1.60 | 0.20 | - | 1.37 | -0.60 | -6.50 | 0.28 |
| R&D Expense | 172.40M | 172.00M | 133.10M | 86.70M | 100.50M | 100.10M | 93.80M | 99.10M | 114.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 5.99B | 5.84B | 6.16B | 6.88B | - | 6.59B | 6.61B | 5.35B | 5.68B |
| Current Assets | - | - | - | - | - | 1.42B | 1.74B | 1.79B | 2.03B |
| Cash & Equivalents | - | 0 | 211.20M | 888.90M | - | 606.90M | 940.00M | 1.07B | 1.21B |
| Inventory | - | - | - | - | - | 300.80M | 258.80M | 241.00M | 288.10M |
| Receivables | - | - | - | - | - | 393.50M | 407.50M | 363.00M | 429.60M |
| Total Liabilities | - | - | - | - | - | 2.38B | 2.43B | 2.42B | 2.57B |
| Current Liabilities | - | 641.00M | 709.20M | 1.68B | - | 1.24B | 780.80M | 878.70M | 852.60M |
| Long Term Debt | - | 0 | 1.32B | 907.70M | - | 870.70M | 1.40B | 1.28B | 1.45B |
| Total Debt | - | - | - | - | - | 1.53B | 1.65B | 1.55B | 1.60B |
| Total Equity | - | 4.82B | 3.54B | 3.72B | - | 4.21B | 4.17B | 2.93B | 3.11B |
| Shares Outstanding | - | - | - | - | - | 163.70M | 173.30M | 174.20M | 175.40M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 359.10M | 400.10M | 397.50M | 283.90M | - | 182.70M | 275.70M | 336.50M | 275.70M |
| Investing Cash Flow | -54.90M | -75.50M | -78.40M | -69.10M | - | -657.30M | -62.40M | -54.60M | -51.10M |
| Financing Cash Flow | -304.20M | -324.60M | -107.70M | 492.50M | - | 12.50M | 118.90M | -103.70M | -170.90M |
| Capital Expenditure | -48.90M | -72.20M | -77.80M | -47.70M | - | -75.70M | -58.20M | -33.80M | -45.30M |
| Free Cash Flow | 310.20M | 327.90M | 319.70M | 236.20M | - | 107.00M | 217.50M | 302.70M | 230.40M |
| Net Change in Cash | - | - | - | - | - | -462.10M | 332.20M | 178.20M | 53.70M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 57.7% | 56.3% | 59.1% | 54.7% | - | 57.4% | 56.1% | 54.7% | 54.7% |
| Operating Margin % | 13.8% | 10.5% | 10.3% | 2.3% | - | 13.4% | 12.3% | 5.5% | 8.7% |
| Net Margin % | 10.7% | 8.1% | 9.5% | 1.7% | - | 9.5% | -3.9% | -44.6% | 1.7% |
| ROE % | - | 4.8% | 6.1% | 0.9% | - | 5.8% | -2.4% | -38.1% | 1.5% |
| ROCE % | - | 5.7% | 4.3% | 0.8% | - | 6.4% | 5.4% | 3.1% | 4.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 11.48% | 18.44M | $430.52M |
| 2 | Ariel Investments, LLC | 6.11% | 9.82M | $229.25M |
| 3 | Dimensional Fund Advisors LP | 5.96% | 9.57M | $223.39M |
| 4 | Vanguard Portfolio Management LLC | 4.66% | 7.49M | $174.84M |
| 5 | Vanguard Capital Management LLC | 4.57% | 7.34M | $171.34M |
| 6 | Morgan Stanley | 4.01% | 6.44M | $150.28M |
| 7 | Gates Capital Management, Inc. | 3.46% | 5.55M | $129.65M |
| 8 | State Street Corporation | 3.32% | 5.33M | $124.44M |
| 9 | Alliancebernstein L.P. | 3.25% | 5.21M | $121.74M |
| 10 | Arrowstreet Capital, Limited Partnership | 3.02% | 4.85M | $113.20M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NVST
Envista Announces Participation in Baird 2026 Global Healthcare Conference
Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in the Baird 2026 Global Healthcare Conference. The fireside chat will take place on Tuesday, September 15, 2026, from 9:40 – 10:10 AM E…
Envista Holdings Shares Rise After JPMorgan Upgrade
Envista Holdings Corp. (NYSE:NVST) shares rose 2.
Envista (NVST) Stock May Be 42% Undervalued On Cash Flow
Envista Holdings arrives at a tricky valuation point for investors, with an intrinsic value estimate from a Discounted Cash Flow (DCF) suggesting the stock may trade below its underlying cash flow value, while market based multiples make th…
New Strong Buy Stocks for August 27th
NVST, VIRT, ONTO, HMN and PROV have been added to the Zacks Rank #1 (Strong Buy) List on August 27th, 2026.
Envista (NVST) Upgraded to Strong Buy: Here's What You Should Know
Envista (NVST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Do Options Traders Know Something About Envista Stock We Don't?
Investors need to pay close attention to NVST stock based on the movements in the options market lately.
NVST — Frequently Asked Questions
What is the current share price of Envista Holdings Corporation (NVST)?
As of 2026-09-19 21:16 PDT, Envista Holdings Corporation (NVST) trades at $26.81 on NYSE. Its 52-week range is $18.95 to $30.26.
What is the market capitalisation of NVST?
Envista Holdings Corporation (NVST) has a market capitalisation of $4.31B on NYSE.
What is the P/E ratio of NVST?
NVST trades at a trailing price-to-earnings (P/E) ratio of 46.22. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.22.
What is the return on equity (ROE) of NVST?
NVST has a return on equity (ROE) of 3.06%. Its return on capital employed (ROCE) is 4.89%.
Is NVST a good stock to buy?
This page provides a data-driven analysis of Envista Holdings Corporation (NVST), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.